The effects of lower intensity anticoagulation therapy on coagulation system in patients with mechanical prosthetic valves.
To evaluate the effect of lower intensity anticoagulation therapy in patients with mechanical prosthetic valves, laboratory-based hematological assays including prothrombin time (PT), activity of factor X, antithrombin III (AT III), D-dimer, fibrinogen (Fg) and platel et al pha-granular membrane protein (GMP-140) were performed in 65 patients who had been on warfarin treatment for over one month. The patients were assigned to 3 groups on the basis of their International Normalized Ratios (INR), ranging from 2.00 to 2.50; 2.51 to 3.00; 3.01 to 4.50, respectively. The results showed that the D-dimer, Fg, GMP-140 levels were higher after mechanical valve replacement than those before operation, indicating the activation of coagulation and fibrinolysis system and the damage of platelets. Lower intensity anticoagulation therapy (INR 2.00 to 2.50) could effectively inhibit the activity of factor X and increase the level of AT III. There were no appreciable differences among D-dimer, Fg, GMP-140 and AT III in the 3 anticoagulation intensity groups. These results suggest that in patients with new generation mechanical prosthetic valves, target anticoagulation level (INR 2.00 to 2.50) may result in good protection from thrombo-embolism.
Du
X
X
Department of Cardiovascular Surgery, Xiehe Hospital Tongji Medical University, Wuhan 430022.
Zhang
K
K
Hu
Z
Z
Lan
H
H
Luo
J
J
Jin
Y
Y
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D005170:Factor X / Q000378:metabolism; D005260:Female; D006349:Heart Valve Diseases / Q000188:drug therapy* / Q000601:surgery; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control; D012214:Rheumatic Heart Disease / Q000188:drug therapy* / Q000601:surgery; D013923:Thromboembolism / Q000517:prevention & control; D014859:Warfarin / Q000627:therapeutic use*
D000925:Anticoagulants; D019007:P-Selectin; D014859:Warfarin; D005170:Factor X